Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY), a developer of therapies targeting obesity, sarcopenia, and longevity, announced on Wednesday that the European Medicines Agency has approved Part I of its Clinical Trial Application for BIO101 (20-hydroxyecdysone).
The Phase 2 OBA study will evaluate the drug in patients with muscle wasting linked to obesity.
The EMA's favourable review validates the quality, safety, and preclinical and clinical data supporting trial initiation.
Biophytis expects to begin patient recruitment in Europe once Part II national-level reviews by Ethics Committees are completed.
The company will now move forward with Part II submissions across European markets. At the same time, Biophytis is advancing its global regulatory strategy, preparing a registration dossier for Brazil following prior interactions with national health authority ANVISA.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval